

4 September 2019

ASX ANNOUNCEMENT

ADMEDUS' CARDIOCEL® 3D APPROVED FOR SALE IN ISRAEL

Structural heart company Admedus Ltd (ASX: AHZ) has received regulatory approval for the sale of the CardioCel® 3D product portfolio in Israel.

The approval of the complete suite of CardioCel® 3D products allows Admedus to service a greater segment of this market, with a solution for the repair of high-complexity congenital heart defects.

Chief Executive Officer, Wayne Paterson said: “The Middle East, which includes Israel, United Arab Emirates, Saudi Arabia and Kuwait, is one of the fastest-growing markets globally, and we are focused on gaining regulatory approvals for our complete 3D range and growing sales in this important region”.

“We are pleased to offer surgeons and patients in Israel access to our CardioCel® 3D range which remains the first and only 3D-shaped bioscaffold on the market and offers the superior clinical benefits of the ADAPT® portfolio’s unique calcification resistance”.

ENDS

For more information, please contact:
Admedus@we-buchan.com

About Admedus Limited

Admedus (ASX:AHZ) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com
Facebook: www.facebook.com/Admedus
Twitter: @Admedus

Admedus Limited

Registered Office:

Toowong Tower, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299
E: info@admedus.com W: admedus.com

